UK Cancer Deaths Fall by 29% Since 1980s Despite Rising Cases | Cancer Research UK Report

The rate of cancer mortality in the United Kingdom has fallen substantially since the 1980s, with a nearly one-third decrease observed, according to a recent analysis by Cancer Research UK (CRUK). This decline reflects decades of progress in cancer prevention, earlier diagnosis, and more effective treatments. Although cancer remains a leading cause of death in Britain – accounting for roughly one in four fatalities – the trend offers a measure of hope, even as challenges persist in matching survival rates seen in some other European nations.

A Decade of Declining Rates

The analysis reveals that approximately 247 people per 100,000 now die from cancer annually, a 29% reduction from the peak of around 355 per 100,000 recorded in 1989. More recently, over the past decade, the cancer death rate has decreased by 11%. Specific cancer types have seen even more pronounced improvements. Between 2012-2014 and 2022-2024, death rates for ovarian cancer fell by 19%, stomach cancer by 34%, and lung cancer by 22%. Smaller declines were also noted for bowel cancer (6%), breast cancer (14%), cervical cancer (11%), and leukemia (9%), as well as oesophageal cancer (12%).

These improvements aren’t simply a matter of chance. Factors like the implementation of smoking bans and the widespread rollout of screening programs for breast, bowel, and cervical cancers have played a significant role. The NHS cervical screening programme, for example, has been credited with a 75% reduction in cervical cancer death rates since the 1970s. The introduction of the human papillomavirus (HPV) vaccine in 2008, with over 6.5 million people vaccinated to date, is contributing to further declines in cervical cancer incidence and mortality. You can find more information about the HPV vaccine and its impact here.

Areas of Concern and Rising Rates

Despite the overall positive trend, the picture isn’t uniformly bright. Certain cancer types have seen their death rates increase in the last decade. Kidney cancer deaths are up 5%, liver cancer 14%, eye cancer 26%, and gallbladder cancer 29%. Other cancer types, including thyroid, pancreatic, and melanoma, have shown stable rates. This highlights the complex and varied nature of cancer, and the need for targeted research and prevention strategies for these specific malignancies.

The Impact of an Aging Population and Brexit Challenges

It’s important to note that while death rates are falling, the number of cancer diagnoses is rising. Here’s largely due to the UK’s growing and aging population – more people are living longer, and cancer risk generally increases with age. The overall number of people dying from cancer continues to climb, even as the proportion of the population affected decreases. One person is diagnosed with cancer every 75 seconds in the UK.

Access to innovative cancer treatments is also facing headwinds. A recent report revealed that British cancer patients are being denied access to life-saving drugs and clinical trials due to bureaucratic hurdles and increased costs stemming from Brexit. The UK’s departure from the European Union has “damaged the practical ability” of doctors to offer NHS patients access to cutting-edge treatments available through international clinical trials.

The Role of Research and Future Progress

Dr. Sam Godfrey, science engagement lead at CRUK, emphasized that the falling death rates are a direct result of “decades of crucial scientific breakthroughs,” including preventative vaccines and more targeted therapies. He highlighted the UK’s position as a global leader in cancer research, but cautioned that continued progress is not guaranteed. “It’s essential that the government makes it easier and faster to set up clinical trials, as well as providing NHS staff with the time and space to carry out life-saving research,” he stated.

One example of UK-led research success is abiraterone, a drug developed by CRUK scientists that blocks testosterone from fueling prostate cancer growth, contributing to the 11% decrease in prostate cancer mortality observed over the past decade. You can learn more about Cancer Research UK’s achievements and ongoing work on their website.

NHS Performance and Government Investment

Despite the positive trends, significant challenges remain within the National Health Service (NHS). A Guardian analysis last year found that three-quarters of NHS hospital trusts are failing to meet cancer performance targets, prompting some experts to declare a national emergency. In response, the government recently pledged £2 billion to overhaul cancer services, aiming to accelerate diagnoses, speed up treatment, and improve support for patients. The national cancer plan aims to have all three waiting time standards met by 2029, whereas some targets have not been achieved since 2015.

Understanding Years of Life Lost

Beyond mortality rates, researchers are also using metrics like “years of life lost” (YLL) to assess the broader impact of cancer on society. YLL gives greater weight to deaths occurring at younger ages, providing a more nuanced understanding of the disease’s burden. A study published in Nature found that while the annual average YLL due to cancer has remained relatively stable between 1988-1992 and 2013-2017 (around 2.2-2.3 million years), the distribution of YLL varies significantly between cancer types. For example, pancreatic cancer contributes a disproportionately large share of YLL despite having a lower incidence than cancers like prostate or breast cancer.

Looking ahead, sustained investment in research, streamlined clinical trial processes, and a commitment to addressing the challenges posed by Brexit are crucial to building on the progress made in reducing cancer mortality in the UK. Continued monitoring of cancer incidence and mortality rates, alongside metrics like YLL, will be essential for informing public health strategies and ensuring that the benefits of scientific advancements reach all those affected by this devastating disease.